Share Issue/Capital Change • Mar 8, 2023
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 3552S
Allergy Therapeutics PLC
08 March 2023
Allergy Therapeutics plc
Block Listing Interim Review
Date 8 March 2023
| Name of applicant: | ALLERGY THERAPEUTICS PLC | |||
| Name of scheme: | Allergy Therapeutics plc 2013 Long Term Incentive Plan | |||
| Period of return: | From: | 1 August 2022 | To: | 28 February 2023 |
| Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: | 10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017 | |||
| Balance of unallotted securities under scheme(s) from previous return: | 7,118,772 ordinary shares | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | Nil | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 7,118,772 ordinary shares | |||
| Name of contact: | Karley Cheesman |
| Telephone number of contact: | +44 (0) 1903 844 700 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLREAXDPEAXDEFA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.